Navigation Links
Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Date:9/13/2011

s, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that elagolix will not proceed to later stage clinical trials for uterine fibroids; risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; risk that elagolix Phase III clinical trials will be delayed or not successfully initiated; risk that elagolix Phase III clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis; risk associated with the Company's dependence on corporate collaborators for clinical development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Co
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
3. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
4. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
5. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
6. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
7. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
8. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
10. Neurocrine Biosciences Reports Third Quarter 2010 Results
11. Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 RadiologyAuction will have their first auction starting ... demonstrations at the end of the auction on May ... and Fuji Cr,s, Agfa and Sony, printers and GE ... Various imaging equipment will be available at later auctions ... years of buying and selling imaging equipment, the brokers ...
(Date:5/4/2015)... , May 4, 2015 PharmaEngine, ... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) with ... BAX ) jointly announced that Baxter has submitted ... Medicines Agency (EMA) for MM-398 (irinotecan liposome injection), ... adenocarcinoma of the pancreas who have been previously ...
(Date:5/4/2015)... May 4, 2015  Makindus, Inc. a specialty pharmaceutical ... European Medicines Agency (EMA) has granted orphan drug designation ... Stargardt,s Disease. "We are extremely pleased to ... Stargardt,s disease in place for Europe ... the United States for which ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2
... GRASS VALLEY, Calif., Jan. 18, 2011 Eigen, a ... announced the completion of the company,s restructuring plan designed ... billion urology medical device marketplace. The company ... is now positioned with a unified management team and ...
... 2011 Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: ... today announced financial results of the three months ended ... the noninvasive treatment of cardiovascular diseases. In addition, the ... VasoHealthcare , commenced operations on July 1, 2010 under ...
Cached Medicine Technology:Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 3Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 4
(Date:5/5/2015)... (PRWEB) May 05, 2015 The ... for assessing and treating children with feeding and ... the course of 20 years through the clinical ... Kay Toomey , in conjunction with colleagues from ... dieticians, and speech pathologists. Education Resources Inc. is ...
(Date:5/5/2015)... NJ (PRWEB) May 05, 2015 Texting has ... is no surprise that some physicians text as a way ... we urge providers who are doing so to assure medical ... does not come without risk! When providers transmit protected ... mobile devices, they run the risk of violating the Health ...
(Date:5/5/2015)... Curly Hair Solutions™ is delighted to introduce the ... Mist. The collection has every curl type covered, ... loose to medium body curls is exposure to the ocean ... fancying the ocean breeze needn’t leave their bathroom. , ... Mist produces the same invigorating freshness one gets when exposed ...
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 Lauren ... goods retailer City Sports , was named one ... and active lifestyle industry by the SportsOneSource ... , Ms. Blanda, 33, is one of 40 executives ... Sporting Goods Business magazine) recognized for exceptional achievement in ...
(Date:5/4/2015)... Parlin dentist, Dr Mariana Blagoev is extending her ... to participate and win a laptop. , Dr. Blagoev created ... good deeds and share them on her Facebook page. By ... teach them to be kind and compassionate when they mature ... years of age and under. Youths are urged to submit ...
Breaking Medicine News(10 mins):Health News:Commission on Dietetic Registration Approves Two Pediatric Feeding Courses Offered by Education Resources Inc. 2Health News:HIPAA Compliant Texting Service from MedXcom now available for Policyholders 2Health News:Curly Hair Solutions Introduces New Revolutionary Product: Curl Keeper Beach Mist 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 3Health News:10 More Days To Enter Good Deed Contest 2
... a connection with obesity risks as they grow up, more so, in ... team of researchers led by Sarah E. Anderson, M.S., from Tufts University ... and 417 men - who underwent assessment four times between 1983 and ... during the beginning of the study, and were in the age group ...
... deteriorate as they progress through puberty, reveals a new ... levels of insulin, however, remain unchanged in their Caucasian ... plays a crucial role in determining the individual risk ... study was conducted by Dr. Geoff Ball and his ...
... Ramadoss said that India is crowned as the diabetic capital. ... national programme for prevention and control of cardiovascular disease, //stroke ... meeting. ,He submitted a draft of the programme ... to make it workable. ,The programme’s main ...
... global network of virus, spyware and spam analysis centers, have warned ... across the internet.// ,This letter claims that lipstick causes ... contain a dangerously high level of lead which can cause cancer. ... claims are not true. ,Sopho has asked the users ...
... incidence of pregnancy complications, more specifically preeclampsia related//, ... Obstetrics and Gynecology. ,Preeclampsia, a pregnancy-related ... (high levels of protein in the urine). Swelling ... seen. If left unattended, the condition can worsen ...
... the women especially the pregnant women about the risks ... as selective serotonin re-uptake inhibitors //(SSRIs) affect the fetus. ... called persistent pulmonary hypertension in babies born to women ... The recent study links SSRIs to this fatal condition ...
Cached Medicine News:Health News:African American Children More Pone to Develop Diabetes 2
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
... provides 5% povidone-iodine solution ... It delivers a microbicidal ... tender to touch. It ... indicated whenever effective microbicidal ...
Medicine Products: